Rainier Acquisition is a blank check company, also known as a special purpose acquisition company (SPAC), that has no operations and generates no revenue. Its purpose is to raise capital through an initial public offering and use the funds to acquire or merge with one or more private businesses to take them public. Rainier focuses primarily on the life sciences industry, targeting companies in therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, and biomanufacturing. Rainier looks for target businesses with differentiated science addressing unmet needs, clear paths to near-term value inflection, and sufficient post-merger capitalization. Under its business model, Rainier holds its offering proceeds in a trust account invested in U.S. Treasuries until a transaction closes. Rainier must complete an acquisition within 24 months, or liquidate the trust and return the funds to public shareholders, who also retain redemption rights during a proposed merger. Rainier's leadership team is primarily affiliated with healthcare investment bank Chardan, leveraging Chardan's industry network to source and execute potential acquisitions.